Dx Deals: Outreach Deals by Quest, Labcorp Are Still Ramping Up
Though the two national players have closed dozens of such deals over the past decade, much runway for new transactions apparently remains
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Though the two national players have closed dozens of such deals over the past decade, much runway for new transactions apparently remains
From - National Intelligence Report
Wrongful payment of electronic health records (EHR) "meaningful use" incentives has become a growth area in federal health care fraud enforcement…
From - G2 Compliance Advisor
Opioid drug-related issues continue to command the lion's share of OIG Work Plan attention, including two of this month's six new items. While none of the new…
From - Laboratory Industry Report
Among the many genetic profiling assays entering the commercial market, few have been more successful than Genomic Heath's Oncotype DX, which is now covered by most of …
From - National Intelligence Report
Molecular next-generation sequencing (NGS) tests have spurred tremendous growth in the lab industry. But as often happens with innovation, NGS technology may be…
From - National Intelligence Report
Thanks for clearing that up. As if the lab industry doesn't already have enough legal agita to deal with, last June a federal D.C. District Court upheld a…
From - G2 Compliance Advisor
Even as your lab makes the transition to the new, supposedly market-based PAMA Medicare Part B fee schedule for tests, big changes may be in store for another rock of…
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
When I was growing up near Buffalo, New York, experiencing two snow storms in three weeks was no big deal; in fact, it was rather commonplace. When I…